{"id":"lumateperone-low-dose","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Orthostatic hypotension"},{"rate":"10-20%","effect":"Weight gain"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Lumateperone acts as a partial agonist at the serotonin 5-HT2A receptor and a dopamine D2 receptor antagonist. This mechanism of action is thought to contribute to its therapeutic effects in treating schizophrenia. Additionally, lumateperone has been shown to modulate glutamatergic neurotransmission, which may also play a role in its therapeutic effects.","oneSentence":"Lumateperone is a serotonin-dopamine antagonist that modulates glutamatergic neurotransmission.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:46.182Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"}]},"trialDetails":[{"nctId":"NCT01499563","phase":"PHASE2","title":"Study of a Novel Antipsychotic ITI-007 in Schizophrenia","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2011-12","conditions":"Schizophrenia","enrollment":335},{"nctId":"NCT06706674","phase":"PHASE3","title":"Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients","status":"RECRUITING","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2024-12-06","conditions":"Irritability Associated With Autism Spectrum Disorder","enrollment":174},{"nctId":"NCT06690398","phase":"PHASE3","title":"Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients","status":"RECRUITING","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2024-11-22","conditions":"Irritability Associated With Autism Spectrum Disorder","enrollment":174}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lumateperone low dose","genericName":"Lumateperone low dose","companyName":"Intra-Cellular Therapies, Inc.","companyId":"intra-cellular-therapies-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lumateperone is a small molecule serotonin 2a (5-HT2a) receptor antagonist, classified as an antagonist. It is being studied as a potential treatment for schizophrenia and irritability associated with autism spectrum disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}